

From: "Sana Alajmovic" <[REDACTED]>

Subject: PRESS RELEASE: Sigrid Therapeutics Presents at the American Diabetes Association 79th Scientific Sessions

Date: Tue, 09 Apr 2019 10:36:19 +0000

Attachments: PRESS_RELEASE_SIGRID_THERAPEUTICS_09042019.pdf

Inline-Images: image001.png

Sigrid Therapeutics Announces SiPore15™ Data Presentation at the American Diabetes Association 79th Scientific Sessions

Stockholm, Sweden, 9 April 2019 – Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies targeting metabolic diseases and disorders, today announces that clinical data for the Company's lead product candidate, SiPore15™, has been selected for presentation as late breaking news at the American Diabetes Association (ADA) 79th Scientific Session, June 7-11, 2019 in San Francisco, California.

The presentation, titled "**Engineered Silica Particles Work as a Molecular Sieve and Reduce Metabolic Risk Factors in Obese Male Volunteers**", will highlight SiPore15™'s mode of action and First-in-Man clinical data. The presentation will be given by Dr. Maria Lindgren, Head of Clinical Development at Sigrid Therapeutics, in the category 12-F Clinical Therapeutics/New Technology–Other Therapeutic Agents.

"We are excited to present details of our lead product candidate SiPore15™ to an international audience of experts dedicated to improving the life of people with diabetes. We are pleased that leading diabetes experts recognize the potential of SiPore15™ to prevent and treat type 2 diabetes in a novel and safer way and we look forward to discussing our data with them", comments Professor Tore Bengtsson, Co-founder and Chief Scientific Officer at Sigrid Therapeutics.

SiPore15™ is under development as a *first-in-class* medical device targeting prediabetics and newly diagnosed type 2 diabetics. First-in-Man clinical trial data confirms that SiPore15™ has a favorable safety profile and significantly reduces blood sugar, blood lipids and body fat composition. SiPore15™ is currently being evaluated in a Proof of Concept clinical trial in prediabetics and newly diagnosed type 2 diabetics in a multicenter trial in Europe (ClinicalTrials.gov Identifier: NCT03823027). The trial has completed full enrollment and topline results will be reported in the fourth quarter of 2019.

About Sigrid Therapeutics AB

Sigrid Therapeutics AB (Sigrid) is a Swedish clinical-stage biotechnology company whose lead product candidate is SiPore15™, a precisely engineered orally ingested material, acting locally in the gut. The material is protected by filed IP and produced to cGMP standards. SiPore15™ is the lead product candidate based on Sigrid's proprietary platform technology SiPore™. Solutions based on the SiPore™ technology have the potential to become breakthrough therapies for a range of preventable metabolic disorders and diseases with high unmet clinical need.

Sigrid Therapeutics AB

Sana Alajmovic
Co-Founder & CEO

Cell: [REDACTED]
Email: [REDACTED]
Skype: sana.alajmovic
Address: Sigrid Therapeutics
Sankt Göransgatan 159
SE-112 17 Stockholm
Sweden
www.sigridthx.com

id:image001.png@01D3597B.CDF71D50

This message is intended only for the use of the Addressee and may contain information that is PRIVILEGED and CONFIDENTIAL. If you are not the intended recipient, you are hereby notified that any use, review, dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please erase all copies of the message and its attachments and notify the sender immediately. Thank you in advance for your cooperation.

Be kind to the environment. Please print this email only if necessary.